Translational Impact Award
The Translational Impact Award is presented to a scientist whose recent (last 10 years) outstanding clinical, environmental health, or translational research has improved human and/or public health in an area of toxicological concern. Scientists who are leaders in multidisciplinary team efforts that have contributed to alleviating toxicity-related health problems are particularly attractive candidates.
The recipient of the 2021 Translational Impact Award will be recognized as part of the Virtual 60th Annual Meeting and ToxExpo.
Making a Nomination
The deadline to submit a nomination is October 9, 2020. Nominations should include both a primary and a secondary letter of nomination from Full members of the Society that provide in layman’s terms an analysis of the nominee’s significant contributions to toxicology and how they apply to the award criteria. The strongest nomination packages include two letters that are distinct from one another to offer more detailed support of the candidate’s qualifications. Nomination packages that include very similar letters of nomination offer less information than those that include recommendations that are varied in content. Letters of nomination should be specific and descriptive while also maintaining a level of concision. The Awards Committee will review only the two letters required to complete the nomination; no additional letters will be considered.
Nominations also should include the nominee’s up-to-date CV. For national SOT Awards, such as the Translational Impact Award, the Awards Committee requires a standardized length for CVs included in nomination packages. CVs must be a maximum of 10 pages in length and should highlight the candidate’s most significant professional accomplishments as they relate to the criteria for the award. Awards Committee members are required to review only 10 pages of each CV; therefore, submitting a longer CV does not strengthen an award nomination.
For more information on making a nomination, please review the “Awards Review Process and FAQs” web page of the SOT website. Please direct any inquiries to SOT Headquarters.
This is an opportunity to honor your colleagues for their outstanding accomplishments; you are encouraged to submit your nominations by October 9.
Spotlight on the 2020 Translational Impact Award Recipient David A. Jett, PhD
Dr. Jett received the 2020 SOT Translational Impact Award for his translational research efforts to develop safer and more effective treatments for highly toxic agent exposure.
After earning his PhD in pharmacology and experimental therapeutics from the University of Maryland in 1992, Dr. Jett conducted his postdoctoral fellowship at the Johns Hopkins University, where he later joined the faculty and led a laboratory focused on organophosphorus pesticides. He then joined the National Institutes of Health (NIH) as a Program Director at the National Institute of Neurological Disorders and Stroke (NINDS), where he worked on programs to increase diversity in the neuroscience workforce and began the development of the NIH Countermeasures Against Chemical Threats (CounterACT) Program in response to a request from the White House Office of Science and Technology Policy.
Currently, Dr. Jett is the Director of the NIH CounterACT program and the Scientific Team Leader within the Division of Translational Research at NINDS, among other intergovernmental responsibilities related to chemical security and public health. Since the program’s establishment in 2006, Dr. Jett and his team of NIH scientists have recruited more than 100 of the nation’s top laboratories into the program, including senior investigators with diverse areas of expertise, including epilepsy, lung disease, toxicology, dermal toxicology, and ophthalmology. The basic and translational research generated by these scientists has resulted in over 1,400 publications in civilian peer-reviewed journals that have provided an unprecedented enrichment in the scientific knowledge base for chemical poisonings. Further, several products initially developed by CounterACT researchers are in the last stages of development, and many more are poised for advanced development in the near term. The approval of Seizalam, now on the market for treating nerve agent exposure, was largely due to a CounterACT-supported clinical trial that Dr. Jett helped organize with several federal agencies. The CounterACT program’s success is owed in large part to Dr. Jett’s “basic to translational” design of the program in its infancy. His efforts in establishing the program earned him and his team the prestigious NIH Director’s Award in 2007.
In addition to his appointment as Professor Adjunct of Epidemiology and Public Health at Yale University, Dr. Jett contributes his expertise to the scientific community through serving on the Neurotoxicology Editorial Board and as a reviewer for many high-impact journals. He has served on state and federal advisory panels and is an active member of the International Neurotoxicology Association, New York Academy of Sciences, and American Society for Experimental Neurotherapeutics, as well as SOT, which he joined in 1993. Dr. Jett is a member of the SOT National Capital Area Regional Chapter, Neurotoxicology Specialty Section, and Clinical and Translational Toxicology Specialty Section.